The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform
Julia Szekeresbartho - One of the best experts on this subject based on the ideXlab platform.
-
progesterone induced Blocking Factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity
Cellular and Molecular Life Sciences, 2013Co-Authors: Melinda Halasz, Beata Polgar, Gergely Berta, Livia Czimbalek, Julia SzekeresbarthoAbstract:Invasiveness is a common feature of trophoblast and tumors; however, while tumor invasion is uncontrolled, trophoblast invasion is strictly regulated. Both trophoblast and tumor cells express high levels of the immunomodulatory progesterone-induced Blocking Factor (PIBF), therefore, we aimed to test the possibility that PIBF might be involved in invasion. To this aim, we used PIBF-silenced or PIBF-treated trophoblast (HTR8/Svneo, and primary trophoblast) and tumor (HT-1080, A549, HCT116, PC3) cell lines. Silencing of PIBF increased invasiveness as well as MMP-2,-9 secretion of HTR8/SVneo, and decreased those of HT-1080 cells. PIBF induced immediate STAT6 activation in both cell lines. Silencing of IL-4Rα abrogated all the above effects of PIBF, suggesting that invasion-related signaling by PIBF is initiated through the IL-4Rα/PIBF-receptor complex. In HTR-8/SVneo, PIBF induced fast, but transient Akt and ERK phosphorylation, whereas in tumor cells, PIBF triggered sustained Akt, ERK, and late STAT3 activation. The late signaling events might be due to indirect action of PIBF. PIBF induced the expression of EGF and HB-EGF in HT-1080 cells. The STAT3-activating effect of PIBF was reduced in HB-EGF-deficient HT-1080 cells, suggesting that PIBF-induced HB-EGF contributes to late STAT3 activation. PIBF binds to the promoters of IL-6, EGF, and HB-EGF; however, the protein profile of the protein/DNA complex is different in the two cell lines. We conclude that in tumor cells, PIBF induces proteins, which activate invasion signaling, while—based on our previous data—PIBF might control trophoblast invasion by suppressing proinvasive genes.
-
dydrogesterone supplementation in women with threatened preterm delivery the impact on cytokine profile hormone profile and progesterone induced Blocking Factor
Journal of Reproductive Immunology, 2011Co-Authors: Igor Hudic, Julia Szekeresbartho, Zlatan Fatusic, Babill Straypedersen, Larisa Dizdarevichudic, Anela Latifagic, Nesad Hotic, Lejla Kameric, Amer MandžicAbstract:Abstract Progesterone is indispensable in creating a suitable endometrial environment for implantation, and also for the maintenance of pregnancy. Successful pregnancy depends on an appropriate maternal immune response to the fetus. A protein called progesterone-induced Blocking Factor (PIBF) acts by inducing Th2-dominant cytokine production to mediate the immunological effects of progesterone. The aim of this prospective study was to compare serum concentrations of progesterone (P), estradiol (E2), anti-inflammatory (IL-10) and pro-inflammatory (IL-6, TNFα, IFNγ) cytokines, and serum PIBF concentrations in women with threatened preterm delivery who were given progesterone supplementation (study group) with those of women with threatened preterm delivery who were not given progesterone supplementation (control group). After dydrogesterone treatment of patients in the study group, serum PIBF as well as progesterone concentrations significantly increased. Women in this group had significantly higher serum levels of IL-10 than controls. The length of gestation was significantly higher in the group of women who were given progesterone supplementation. Our data suggest that dydrogesterone treatment of women at risk of preterm delivery results in increased PIBF production and IL-10 concentrations, and lower concentrations of IFNγ.
-
endometrial expression of progesterone induced Blocking Factor and galectins 1 3 9 and 3 binding protein in the luteal phase and early pregnancy in cattle
Physiological Genomics, 2011Co-Authors: Lilian A Okumu, T Fair, Julia Szekeresbartho, Alan M Odoherty, M A Crowe, J F Roche, P Lonergan, Niamh FordeAbstract:Progesterone-induced Blocking Factor (PIBF) and galectins modulate the maternal immune response during pregnancy. We hypothesized that the relative transcript abundance of the above genes would be ...
-
maternal serum progesterone induced Blocking Factor at 11 13 weeks gestation in spontaneous early preterm delivery
Fetal Diagnosis and Therapy, 2011Co-Authors: Jarek Beta, Julia Szekeresbartho, Evdoxia Skyfta, Ranjit Akolekar, K H NicolaidesAbstract:Objective: Progesterone-induced Blocking Factor (PIBF) may be the mediator of the pregnancy maintenance effects of progesterone. The aim of this study is to investigate the potential value of measuring the maternal serum concentration of PIBF at 11–13 weeks’ gestation in the prediction of spontaneous early preterm delivery. Method: The maternal serum concentration of PIBF at 11–13 weeks was measured by enzyme-linked immunosorbent assay in 25 singleton pregnancies which subsequently delivered spontaneously before 34 weeks, and 75 controls who delivered at or after 37 weeks. The values in the 2 groups were compared by the Mann-Whitney U test. Results: The median maternal serum concentration of PIBF in women who subsequently delivered before 34 weeks (157.5, interquartile range 99.5–208.8 ng/ml) was not significantly different from the control group delivering at term (167.5, interquartile range 105.0–212.0 ng/ml; p = 0.519). Conclusions: In women who have a spontaneous early preterm delivery, the maternal serum levels of PIBF are not altered at 11–13 weeks of gestation.
-
the impact of dydrogesterone supplementation on hormonal profile and progesterone induced Blocking Factor concentrations in women with threatened abortion
American Journal of Reproductive Immunology, 2005Co-Authors: Jaroslaw Kalinka, Julia SzekeresbarthoAbstract:Problem: The therapeutic value of progestogens in threatened abortion is still under debate. In the presence of sufficient progesterone levels during pregnancy, lymphocytes synthesize a mediator [progesterone-induced Blocking Factor (PIBF)] that is anti-abortive in mice. The aim of this study was to evaluate the effect of dydrogesterone on pregnancy outcome of threatened aborters. Method of Study: Twenty-seven threatened aborters were treated for 10 days with dydrogesterone (30–40 mg/day). Sixteen healthy pregnant controls received no treatment. Serum progesterone and estradiol concentrations as well as urine PIBF concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Results: Pregnancy outcomes in dydrogesterone-treated threatened aborters did not statistically differ from those in healthy controls. Serum progesterone concentrations in control patients, but not those in threatened aborters increased as pregnancy progressed. Following dydrogesterone treatment, initially low PIBF concentrations of threatened aborters significantly increased (P = 0.001) to reach the PIBF level found in healthy controls. Conclusions: These data suggest that by inducing PIBF production, dydrogesterone might improve pregnancy success rates in threatened aborters.
P A Wurtzen - One of the best experts on this subject based on the ideXlab platform.
-
functional rather than immunoreactive levels of igg4 correlate closely with clinical response to grass pollen immunotherapy
Allergy, 2012Co-Authors: Mohamed H Shamji, J. N. Francis, Mark Larché, Christian Ljorring, Ian Kimber, Anthony J. Frew, Moises A Calderon, Kaare Lund, Henrik Ipsen, P A WurtzenAbstract:To cite this article: Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, Frew AJ, Ipsen H, Lund K, Wurtzen PA, Durham SR. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67: 217–226. Abstract Background: Induction of allergen-specific IgG4 antibodies is the most consistent immunological finding in immunotherapy trials. However, quantitative assessments of IgG4 antibodies have not proven beneficial in evaluating clinical changes during or after immunotherapy. In the current study, we investigated the relationship between clinical outcome and allergen-specific IgG4 titres or functional antibody responses following immunotherapy. We hypothesized that functional assays of serum IgG–associated inhibitory activity such as inhibition of IgE–allergen interactions (IgE-Blocking Factor) and inhibition of CD23-dependent IgE-facilitated allergen binding (IgE-FAB) correlate more closely with clinical outcome and may be biomarkers of clinical response. Methods: In an 8-month dose–response randomized double-blind placebo-controlled study, 221 polysensitized subjects with severe seasonal rhinitis received Alutard SQ, Phleum pratense 100 000 SQ-U, 10 000 SQ-U or placebo injections. Serum specimens were collected before treatment, after up-dosing, during the peak season and at the end of the study. Allergen-specific IgG4 titres and IgG-associated inhibitory activity were evaluated. Results: A time- and dose-dependent increase in serum inhibitory activity for both the IgE-Blocking Factor and IgE-FAB was observed, which paralleled increases in grass pollen–specific IgG4 antibodies. A modest but significant inverse relationship was demonstrated between postimmunotherapy serum inhibitory activity and combined symptom–rescue medication scores (IgE-FAB: r = −0.25, P = 0.0002; IgE-Blocking Factor: r = −0.28, P < 0.0001), whereas this was not observed for immunoreactive IgG4 levels (r = −0.11, P = 0.12). Conclusions: Functional assays of inhibitory IgG4 and IgE-Blocking Factor may be more useful surrogates of clinical response than IgG4. Whether these antibody effects may serve as predictive biomarkers of clinical efficacy in individual patients requires further investigation.
-
Functional rather than immunoreactive levels of IgG4correlate closely with clinical response to grass pollen immunotherapy
Allergy: European Journal of Allergy and Clinical Immunology, 2012Co-Authors: Mohamed H Shamji, Mauricio Calderón, J. N. Francis, Mark Larché, Christian Ljorring, Ian Kimber, Anthony J. Frew, Kaare Lund, Henrik Ipsen, P A WurtzenAbstract:Induction of allergen-specific IgG(4) antibodies is the most consistent immunological finding in immunotherapy trials. However, quantitative assessments of IgG(4) antibodies have not proven beneficial in evaluating clinical changes during or after immunotherapy. In the current study, we investigated the relationship between clinical outcome and allergen-specific IgG(4) titres or functional antibody responses following immunotherapy. We hypothesized that functional assays of serum IgG-associated inhibitory activity such as inhibition of IgE-allergen interactions (IgE-Blocking Factor) and inhibition of CD23-dependent IgE-facilitated allergen binding (IgE-FAB) correlate more closely with clinical outcome and may be biomarkers of clinical response.
Mohamed H Shamji - One of the best experts on this subject based on the ideXlab platform.
-
functional rather than immunoreactive levels of igg4 correlate closely with clinical response to grass pollen immunotherapy
Allergy, 2012Co-Authors: Mohamed H Shamji, J. N. Francis, Mark Larché, Christian Ljorring, Ian Kimber, Anthony J. Frew, Moises A Calderon, Kaare Lund, Henrik Ipsen, P A WurtzenAbstract:To cite this article: Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, Frew AJ, Ipsen H, Lund K, Wurtzen PA, Durham SR. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67: 217–226. Abstract Background: Induction of allergen-specific IgG4 antibodies is the most consistent immunological finding in immunotherapy trials. However, quantitative assessments of IgG4 antibodies have not proven beneficial in evaluating clinical changes during or after immunotherapy. In the current study, we investigated the relationship between clinical outcome and allergen-specific IgG4 titres or functional antibody responses following immunotherapy. We hypothesized that functional assays of serum IgG–associated inhibitory activity such as inhibition of IgE–allergen interactions (IgE-Blocking Factor) and inhibition of CD23-dependent IgE-facilitated allergen binding (IgE-FAB) correlate more closely with clinical outcome and may be biomarkers of clinical response. Methods: In an 8-month dose–response randomized double-blind placebo-controlled study, 221 polysensitized subjects with severe seasonal rhinitis received Alutard SQ, Phleum pratense 100 000 SQ-U, 10 000 SQ-U or placebo injections. Serum specimens were collected before treatment, after up-dosing, during the peak season and at the end of the study. Allergen-specific IgG4 titres and IgG-associated inhibitory activity were evaluated. Results: A time- and dose-dependent increase in serum inhibitory activity for both the IgE-Blocking Factor and IgE-FAB was observed, which paralleled increases in grass pollen–specific IgG4 antibodies. A modest but significant inverse relationship was demonstrated between postimmunotherapy serum inhibitory activity and combined symptom–rescue medication scores (IgE-FAB: r = −0.25, P = 0.0002; IgE-Blocking Factor: r = −0.28, P < 0.0001), whereas this was not observed for immunoreactive IgG4 levels (r = −0.11, P = 0.12). Conclusions: Functional assays of inhibitory IgG4 and IgE-Blocking Factor may be more useful surrogates of clinical response than IgG4. Whether these antibody effects may serve as predictive biomarkers of clinical efficacy in individual patients requires further investigation.
-
Functional rather than immunoreactive levels of IgG4correlate closely with clinical response to grass pollen immunotherapy
Allergy: European Journal of Allergy and Clinical Immunology, 2012Co-Authors: Mohamed H Shamji, Mauricio Calderón, J. N. Francis, Mark Larché, Christian Ljorring, Ian Kimber, Anthony J. Frew, Kaare Lund, Henrik Ipsen, P A WurtzenAbstract:Induction of allergen-specific IgG(4) antibodies is the most consistent immunological finding in immunotherapy trials. However, quantitative assessments of IgG(4) antibodies have not proven beneficial in evaluating clinical changes during or after immunotherapy. In the current study, we investigated the relationship between clinical outcome and allergen-specific IgG(4) titres or functional antibody responses following immunotherapy. We hypothesized that functional assays of serum IgG-associated inhibitory activity such as inhibition of IgE-allergen interactions (IgE-Blocking Factor) and inhibition of CD23-dependent IgE-facilitated allergen binding (IgE-FAB) correlate more closely with clinical outcome and may be biomarkers of clinical response.
Jaroslaw Kalinka - One of the best experts on this subject based on the ideXlab platform.
-
the impact of dydrogesterone supplementation on hormonal profile and progesterone induced Blocking Factor concentrations in women with threatened abortion
American Journal of Reproductive Immunology, 2005Co-Authors: Jaroslaw Kalinka, Julia SzekeresbarthoAbstract:Problem: The therapeutic value of progestogens in threatened abortion is still under debate. In the presence of sufficient progesterone levels during pregnancy, lymphocytes synthesize a mediator [progesterone-induced Blocking Factor (PIBF)] that is anti-abortive in mice. The aim of this study was to evaluate the effect of dydrogesterone on pregnancy outcome of threatened aborters. Method of Study: Twenty-seven threatened aborters were treated for 10 days with dydrogesterone (30–40 mg/day). Sixteen healthy pregnant controls received no treatment. Serum progesterone and estradiol concentrations as well as urine PIBF concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Results: Pregnancy outcomes in dydrogesterone-treated threatened aborters did not statistically differ from those in healthy controls. Serum progesterone concentrations in control patients, but not those in threatened aborters increased as pregnancy progressed. Following dydrogesterone treatment, initially low PIBF concentrations of threatened aborters significantly increased (P = 0.001) to reach the PIBF level found in healthy controls. Conclusions: These data suggest that by inducing PIBF production, dydrogesterone might improve pregnancy success rates in threatened aborters.
-
the impact of dydrogesterone supplementation on hormonal profile and progesterone induced Blocking Factor concentrations in women with threatened abortion
American Journal of Reproductive Immunology, 2005Co-Authors: Jaroslaw Kalinka, Julia SzekeresbarthoAbstract:PROBLEM: The therapeutic value of progestogens in threatened abortion is still under debate. In the presence of sufficient progesterone levels during pregnancy, lymphocytes synthesize a mediator [progesterone-induced Blocking Factor (PIBF)] that is anti-abortive in mice. The aim of this study was to evaluate the effect of dydrogesterone on pregnancy outcome of threatened aborters. METHOD OF STUDY: Twenty-seven threatened aborters were treated for 10 days with dydrogesterone (30-40 mg/day). Sixteen healthy pregnant controls received no treatment. Serum progesterone and estradiol concentrations as well as urine PIBF concentrations were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: Pregnancy outcomes in dydrogesterone-treated threatened aborters did not statistically differ from those in healthy controls. Serum progesterone concentrations in control patients, but not those in threatened aborters increased as pregnancy progressed. Following dydrogesterone treatment, initially low PIBF concentrations of threatened aborters significantly increased (P = 0.001) to reach the PIBF level found in healthy controls. CONCLUSIONS: These data suggest that by inducing PIBF production, dydrogesterone might improve pregnancy success rates in threatened aborters.
Gabriel Oksa - One of the best experts on this subject based on the ideXlab platform.
-
PPAM (1) - Parallel One–Sided Jacobi SVD Algorithm with Variable Blocking Factor
Parallel Processing and Applied Mathematics, 2014Co-Authors: Martin Becka, Gabriel OksaAbstract:Parallel one-sided block-Jacobi algorithm for the matrix singular value decomposition (SVD) requires an efficient computation of symmetric Gram matrices, their eigenvalue decompositions (EVDs) and an update of matrix columns and right singular vectors by matrix multiplication. In our recent parallel implementation with \(p\) processors and Blocking Factor \(\ell =2p\), these tasks are computed serially in each processor in a given parallel iteration step because each processor contains exactly two block columns of an input matrix \(A\). However, as shown in our previous work, with increasing \(p\) (hence, with increasing Blocking Factor) the number of parallel iteration steps needed for the convergence of the whole algorithm increases linearly but faster than proportionally to \(p\), so that it is hard to achieve a good speedup. We propose to break the tight relation \(\ell =2p\) and to use a small Blocking Factor \(\ell = p/k\) for some integer \(k\) that divides \(p\), \(\ell \) even. The algorithm then works with pairs of logical block columns that are distributed among processors so that all computations inside a parallel iteration step are themselves parallel. We discuss the optimal data distribution for parallel subproblems in the one-sided block-Jacobi algorithm and analyze its computational and communication complexity. Experimental results with full matrices of order \(8192\) show that our new algorithm with a small Blocking Factor is well scalable and can be \(2\)–\(3\) times faster than the ScaLAPACK procedure PDGESVD.
-
parallel one sided jacobi svd algorithm with variable Blocking Factor
International Conference on Parallel Processing, 2013Co-Authors: Martin Becka, Gabriel OksaAbstract:Parallel one-sided block-Jacobi algorithm for the matrix singular value decomposition (SVD) requires an efficient computation of symmetric Gram matrices, their eigenvalue decompositions (EVDs) and an update of matrix columns and right singular vectors by matrix multiplication. In our recent parallel implementation with \(p\) processors and Blocking Factor \(\ell =2p\), these tasks are computed serially in each processor in a given parallel iteration step because each processor contains exactly two block columns of an input matrix \(A\). However, as shown in our previous work, with increasing \(p\) (hence, with increasing Blocking Factor) the number of parallel iteration steps needed for the convergence of the whole algorithm increases linearly but faster than proportionally to \(p\), so that it is hard to achieve a good speedup. We propose to break the tight relation \(\ell =2p\) and to use a small Blocking Factor \(\ell = p/k\) for some integer \(k\) that divides \(p\), \(\ell \) even. The algorithm then works with pairs of logical block columns that are distributed among processors so that all computations inside a parallel iteration step are themselves parallel. We discuss the optimal data distribution for parallel subproblems in the one-sided block-Jacobi algorithm and analyze its computational and communication complexity. Experimental results with full matrices of order \(8192\) show that our new algorithm with a small Blocking Factor is well scalable and can be \(2\)–\(3\) times faster than the ScaLAPACK procedure PDGESVD.
-
On variable Blocking Factor in a parallel dynamic block: Jacobi SVD algorithm
Parallel Computing, 2003Co-Authors: Martin Becka, Gabriel OksaAbstract:The parallel two-sided block-Jacobi singular value decomposition (SVD) algorithm with dynamic ordering, originally proposed in [Parallel Comput. 28 (2002) 243-262], has been extended with respect to the Blocking Factor l. Unlike the unique Blocking Factor l = 2p in the original algorithm running on p processors, the current Blocking Factor is a variable parameter that covers the values in two different regions--namely, l = p/k and l = 2kp for some integer k. Two new parallel two-sided block-Jacobi SVD algorithms with dynamic ordering are described in detail. They arise in those two regions and differ in the logical data arrangement and communication complexity of the reordering step. For the case of l = 2kp, it is proved that a designed point-to-point communication algorithm is optimal with respect to the amount of communication required per processor as well as to the amount of overall communication. Using the message passing programming model for distributed memory machines, new parallel block-Jacobi SVD algorithms were implemented on an SGI-Cray Origin 2000 parallel computer. Numerical experiments were performed on p = 12 and 24 processors using a set of six matrices of order 4000 and Blocking Factors l, 2 ≤ l ≤ 192. To achieve the minimal total parallel execution time, the use of a Blocking Factor l ∈ {2,p, 2p} can be recommended for matrices with distinct singular values. However, for matrices with a multiple minimal singular value, the total parallel execution time may monotonically increase with l. In this case, the recommended Jacobi method with l = 2 is just the ScaLAPACK routine with some additional matrix multiplications, and it computes the SVD in one parallel iteration step.